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Abstract 
Epigenetics, and more specifically DNA methylation is a fast evolving research area. In almost every cancer 
type, each month new publications confirm the differentiated regulation of specific genes due to 
methylation and mention the discovery of novel methylation markers. Therefore, it would be extremely 
useful to have an annotated, reviewed, sorted and summarized overview of all available data. PubMeth is a 
cancer methylation database that includes genes that are reported to be methylated in various cancer types. 
A query can be based either on genes (to check in which cancer types the genes are reported as being 
methylated) or on cancer types (which genes are reported to be methylated in the cancer (sub) types of 
interest). The database is freely accessible at http://www.pubmeth.org. 
PubMeth is based on text-mining of Medline/PubMed abstracts, combined with manual reading and 
annotation of preselected abstracts. The text-mining approach results in increased speed and selectivity (as 
for instance many different aliases of a gene are searched at once), while the manual screening significantly 
raises the specificity and quality of the database. The summarized overview of the results is very useful in 
case more genes or cancer types are searched at the same time. 
Introduction 
 
DNA methylation represents a modification of DNA by addition of a methyl group to a cytosine, also referred 
to as the fifth base (1).  This reaction uses S-adenosyl-methionine as a methyl donor and is catalyzed by a 
group of enzymes, the DNA methyltransferases (DNMTs). In humans and other mammals, this epigenetic 
modification is almost exclusively imposed on cytosines that precede a guanosine in the primary DNA 
sequence (often called a CpG dinucleotide). The frequency of these CpGs in the genome is much lower than 
would be expected as a methylated cytosine often is subject to deamination thereby forming thymidine. 
However, in some regions, dense clusters of CpGs can be identified: these regions are referred to as CpG 
islands (2). 
DNA-methylation is an epigenetic change: it does not alters the primary DNA sequence and might contribute 
to overall genetic stability and maintenance of chromosomal integrity. Consequently, it facilitates the 
organization of the genome into active and inactive regions with respect to gene transcription (3). Genes 
with CpG islands in their promoter region are generally unmethylated in normal tissues. Upon DNA 
hypermethylation, transcription of the affected genes may be blocked, resulting in gene silencing. In 
neoplasia, abnormal patterns of DNA methylation have been recognized. Hypermethylation is now 
considered one of the important mechanisms resulting in silencing expression of tumour suppressor genes, 
i.e. genes responsible for control of normal cell differentiation and/or inhibition of cell growth. In the last 
few years, new hypermethylated biomarkers have been used in cancer research and diagnostics (4). 
MethDB (5), one of the few databases that focus on DNA methylation, is general and sample oriented. But it 
is not optimized to cancer-related queries because this type of query requires a summarized overview. 
However, in MethDB querying multiple genes or cancer types is not supported and data is always handled as 
a separate sample. Another database, MethPrimerDB (6), has a focus on detection methodologies (e.g. MSP 
primer design). Both databases discussed here, depend on submissions by administrators or users, which 
guarantees the required quality of the databases, but consequently they are not always complete and up to 
date. The databases are neither designed to rank and summarize cancer-related information (genes and 
cancer (sub) types involved), although this is crucial in applied methylation research in the cancer field. 
Hereby we present PubMeth, a database that combines a text-mining approach (fast, intelligent to search 
multiple aliases and textual variants of these aliases, querying multiple keyword lists at once) with a manual 
reviewing and annotation step. The latter one drastically improves specificity and annotation quality.  The 
interface is able to rank, summarize and represent data, making the information the database contains easily 
accessible. 
The reviewing step also heavily depends on the text-mining step that sorts abstracts, highlights terms and 
provides links to different sources. This way, the reviewing step can be done fast and accurate enough to 
process all abstracts, electronically published until now in PubMed. In addition, using this approach, an 
update strategy can be more easily implemented. 
DNA methylation in cancer research has evolved to a mainstream research topic. Methylation profiles are 
successfully used in early detection and personalized treatment. However, more and more data is available, 
especially with the availability of large-scale screening techniques. All the information taken together 
determines the knowledge of the ‘cancer methylome’. Ultimately, the epigenome of all cancer tissues, 
including those of different stage and grade, could be mapped out. Epigenetic states differ widely among 
tissues, and changes are far more varied and much more frequent per tumor than DNA mutations. "Each 
differentiated cell has a different epigenome," said Jones (7). In this perspective, it is very useful to extract 
which genes are already reported in which cancer types from literature. This information might be used as 
positive controls, to check the same genes in other (related) cancer types, to screen for markers that could 
be used as early diagnostic utility or in the context of personalized medicine and to deepen the knowledge of 
the mechanisms of methylation.  
PubMeth tries to contain and summarize as many available literature data and presents them in a easy to 
use graphical interface. It speeds up the process of searching relevant literature, many aliases and keywords 
are searched at the same time and the results are reliable as they are manually reviewed as one would do 
when performing a manual literature search. 
Filling up the database 
 
Abstracts, related with epigenetics and methylation, are downloaded in XML-format through NCBI E-Utils (E-
fetch) using more than 15 methylation-related keywords (such as methylation, DNA-methylation, 
methylated, epigenetic and a range of variants, as well as detection technologies). The aliases, symbols and 
descriptions of human genes, associated with an Ensembl ID, are obtained using a perl-script. This queries 
the GeneCards database (8), that already combines different genetic databases such as Ensembl and Entrez 
Gene. Different textual variations of all aliases are generated to be as complete as possible (e.g. variants for 
BRCA1 include BRCA 1, BRCA-1, BRCAI, BRCA I and BRCA-I). To avoid counting and highlighting aliases that 
are also common English words, an alias is rejected if more than 100,000 PubMed abstracts are retrieved. A 
list (http://www.wordcount.org) of frequently used English words is searched at the same time. 
Cancer-related keywords were obtained from a list of the National Cancer Institute 
(http://www.cancer.gov/cancertopics/alphalist) and keywords related with detection-methodologies are 
manually compiled. 
One by one, abstracts are searched for aliases and their variants, methylation-related keywords, sentences 
with both an alias and such a keyword. In addition, terms related with cancer and detection methodology 
are also highlighted and counted. This information is stored in a MySQL 5 relational database using Perl-DBI. 
Based on the information in this database, abstracts are ranked. This ranking is based on a large number of 
parameters such as the number of aliases, the number of different genes, the number of different aliases per 
gene, the number of sentences with both an alias and a methylation-related keyword, the presence of 
detection-methodology and cancer-related keywords. 
Abstracts are then manually reviewed, taking the order after ranking into account, with the aid of 
highlighting the different keyword lists, aliases and sentences with alias and methylation-related keyword in 
different colours. Aliases are linked with gene information using hover-over effects generated with 
JavaScript and CSS. After manual reviewing, the information in the database only has to be minimally 
updated or corrected. A schematic overview of the complete process is given in Figure 1. This process is still 
in progress; due to the ranking system the most important publications are currently in the database. The 
remaining abstracts will be reviewed soon, and an accurate update strategy will be developed. 
 Figure 1: Scheme that illustrates the initial filling up of database using text-mining. Aliases of genes and different keyword lists 
(methylation, cancer and detection-related) are highlighted in the abstract. At the same time, different parameters are counted and 
stored in a MySQL relational database. Afterwards, the data is ranked and manually reviewed. 
Querying the database 
 
A record in the database contains information about the source publication, the gene, the cancer type and 
subtypes if specified. It includes the number of primary cancer samples where methylation is analyzed in, as 
well as the number of analyzed cell lines and the number of normal tissues. For all these three categories the 
methylation frequency (the percentage of the samples that show methylation) is also available. Other 
information includes the detection technologies used and an ‘evidence sentence’ where most of the 
information in this record came from. 
PubMeth can be queried using the web-interface at http://www.pubmeth.org in two ways, depending on 
the researcher’s focus: 
 gene-related:  in which cancer types (and subtypes) the genes of interest are reported to be 
methylated 
 cancer-related: which genes are reported to be methylated in the cancer types/subtypes 
Gene-centric query 
 
A query is created in two easy steps. In the first step, the user provides a list of genes (different identifiers 
are accepted: gene symbol or name, RefSeq, Ensembl ID, …). The query is analyzed using local symbol/alias 
lists, generated using GeneCards, and suggestions are presented to the user. In the second step, the user 
reviews the selections made (most likely the genes selected due to intelligent sorting in the background are 
correct) and submits his choices. 
At this point, the results will be generated and the main result page is presented to the user. This main result 
page ranks the genes, based on the number of references to the gene in the database. A graphical summary 
representation of the number of references, the number of primary samples and the mean methylation 
frequency within different cancer types is also given (example in Figure 2). 
The summary is very useful if multiple genes are searched at once; this feature is what distinguishes this 
database from previous efforts. One practical usage example would be that, using a pharmacologic 
demethylation approach in cell lines, 50 candidate genes are selected. The question then is to sub-select 
genes to verify in primary cancer samples, often based on time-consuming literature searches. This selection 
is facilitated by the summarization view of PubMeth. 
From this main page, one can go to the detailed pages, focusing on a selected gene in a certain cancer type. 
On such a detailed page, graphical representations of the number of references in the database, the total 
number of samples and the mean methylation frequency are displayed for the different cancer types and 
their subtypes. The complete individual records, linked with their original PubMed record, are shown. Users 
can also choose to browse a pre-computed genelist. Advantage is that the user can browse all genes in 
PubMeth without having to query the database, which significantly is faster. However, the summary view is 
not available. 
 
Figure 2: Summary page of a gene-centric query. The different colors represent the frequency of methylation of the gene in the 
different cancer types (what percentage of the samples showed methylation), while the numbers indicate the total number of 
primary samples tested for methylation. 
Cancer-centric query 
 
A cancer-centric query is executed in one easy step: the user selects cancer types (and/or subtypes up to 
three levels – e.g. lymphoma - non-hodgkin lymphoma - b-cell lymphoma -  diffuse large B-cell). An overview 
(in the same style as the gene-centric searching approach) of the genes that are most commonly described 
as methylated in the selected cancer types, as well as the total number of samples and the mean 
methylation frequency is returned. From this summary page, navigating to detailed pages is intuitive. 
This type of search is meant to get a quick overview of the genes that are reported in the methylation 
context in the cancer (sub)types of interest and in which frequency, to explore methylation in the cancer 
types of interest, to compare experimental results with or to perform, in a next step, a gene-centric search 
on these genes for full details in all cancer (sub)types. 
 A screencast that dynamically shows how to query PubMeth is available on the website of PubMeth. 
Performance of PubMeth, discussion and future 
 
To evaluate the performance of PubMeth, we tested how well the database performed in comparison with a 
careful manual literature search. Therefore, we selected a very recent review, focusing on DNA-methylation 
in breast cancer (9). This article contains a table where the authors provide a table with 39 genes, known to 
be hypermethylated in breast cancer and their literature references. The genes in this list are entered into 
the gene-centric search of PubMeth: 27 genes are listed in PubMeth, 11 are not listed and 1 gene could not 
be associated with a gene symbol. Of the 27 genes listed in PubMeth, 20 are described in breast cancer. 
Breast cancer is listed first on the results page due to the background sorting mechanisms, but PubMeth 
seems to have missed 18 genes in breast cancer. 
On the other hand, the review article lists 39 different genes, while a cancer-centric search for breast cancer 
returns 94 genes. Important to mention: the genes both in PubMeth and the review (the shared group) are 
associated with a high number of primary samples in PubMeth. If all 94 genes were ranked according to the 
number of primary samples in decreasing order, most members of the shared group are on top of this 
ranking, almost the complete top-10 is present in the shared group (except numbers 7 and 8). 
This example clearly shows the power of PubMeth as well as its weaknesses. First of all, doing such a 
literature search manually usually takes multiple hours, while PubMeth presents its summary within 
minutes. PubMeth is in most cases able to find more references than a manual search would, using the 
different keywords and aliases lists. On the contrary, often abstracts don’t mention any of the genes in 
question, and these abstract are not taken into account for consideration in PubMeth. This type of articles is 
often a large-scale study with multiple genes or a review. These articles often are easily found by manual 
searches but not using our text mining approach that is only able to screen abstracts.  
As long as there is no universal or centralized system to be able to screen full text articles or a mainstream 
open access strategy, solution for this would be to leave the restriction that the abstract has to contain a 
gene out and to do more general searches. Other possibility is to allow users to enter their suggestions for 
inclusion into PubMeth; such a submission system would allow to combine the power of both submissions 
by users and an automated text mining approach that demonstrates to be very powerful dealing with 
different keyword lists and gene name variants. The latter is available on the PubMeth website: articles 
related with DNA-methylation in cancer that could not be found with PubMeth, can be suggested for 
inclusion. 
Currently, PubMeth only focuses on hypermethylation, however the inclusion of hypomethylated genes 
would be useful as well for some users. In a next update, keywords related with hypomethylation will be 
added. 
Other future database updates should take into account different originating tissues (for example clearly 
separate between primary cancer tissue and serum) and the different types of normals (surrounding tissue 
in tumor patient versus samples from healthy person). However, different articles use different 
terminologies and often this information is not easily extractable. 
Improvements to the interface should represent the above described separation of samples. Currently, only 
the mean of the methylation frequency in primary cancers is given. This could be extended to give an idea of 
the degree of variation in the different experiments and the different methods, the difference between 
cancer and normal tissue and the frequency in cell lines. However, it is a real challenge to present all this 
useful information in a clear interface that is easy to overview and browse. 
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